Judith T. Zelikoff

New York University School
of Medicine
Department of
Environmental Medicine
57 Old Forge Road
Tuxedo Park, NY 10987
845.731.3528
judith.zelikoff@nyumc.org

Dr. Zelikoff has more than 25 years experience using animal models for inhalation toxicology of single contaminants including metals, nanoparticles, gaseous air pollutants, and pollution mixtures including ambient particulate matter (PM) and combustible and non-combustible tobacco and nicotine delivery products. Over the last decade, studies in her laboratory have focused on early life exposures (fetal, perinatal, neonatal) to PM, smoked and smokeless tobacco products, and recently, e-cigarette aerosols, metal nanoparticles, and obstetric consequences and later life disease outcomes including cancer, asthma, cardiovascular disease, attention deficit disorder, and obesity. Dr. Zelikoff is an active member of the Society of Toxicology, including a term on the SOT Council, now serving as incoming Chair of CDI. She received a Lifetime Achievement Award in immunotoxicology from the SOT Immuno-toxicology Specialty Section in 2013 and a Mentorship Award from the Women in Toxicology Special Interest Group in 2015. Dr. Zelikoff has served on several federal and state advisory panels including the Institute of Medicine and National Research Council, EPA, NASA, NTP, and NJ Department of Environmental Protection. In addition to serving as an Associate Editor and Editorial Board member for numerous toxicology and environmental health journals, she currently serves as Vice-President for the New York University (NYU) School of Medicine Faculty Council, as well as Director for the NYU NIEHS Center Community Outreach & Engagement Core for over 8 years. In addition, she teaches several courses in toxicology and immunotoxicology at NYU, as well as holding a joint faculty appointment with the Chulabhorn Research Institute in Bangkok and with the University of Lagos (Nigeria). Her most recent work explores the health impacts associated with exposure to fracking fluids and electronic waste products.

Kimberly Hodge-Bell

Monsanto Company
Product Safety Center
800 N. Lindbergh Boulevard
St. Louis, MO 63167
314.694.8244
kimberly.c.hodge-bell@monsanto.com

Dr. Hodge-Bell is an Associate Fellow and Senior Toxicologist at Monsanto Company. She is responsible for providing technical expertise in support of commercialization and regulatory submissions for biotechnology-derived and crop protection products. Dr. Hodge-Bell earned her doctorate degree in Biomedical Science (Pharmacology and Toxicology) from Meharry Medical College and completed a postdoctoral fellowship at the University of California, Los Angeles. She is a Diplomate of the American Board of Toxicology. As an active member in the Society of Toxicology, Dr. Hodge-Bell serves on several elected and appointed committees. Currently, she is a member of the Committee on Diversity Initiatives and serves as the 2016-2017 Co-Chair. She is also a member of the Toxicologist of African Origin Special Interest Group and served as its President in 2014-2015. Dr. Hodge-Bell's technical excellence, leadership style and passion for equipping the next generation of scientists often drives her to participate in outreach efforts such as speaking at colleges and universities, serving as a Scientific Ambassador within the community and participating in mentorship programs.

Antonio T. Baines

North Carolina Central University
Biology
Mary Townes Science Building 1801 Fayetteville Street Durham, NC 27707
979.540.6500
abaines@nccu.edu

Science was always one of the courses that Dr. Antonio (Tony) Baines excelled in throughout high school. It was this love for science that led him to major in biology as an honor student at Norfolk State University in Norfolk, Virginia. Dr. Baines first experience with toxicology began during his sophomore year of college when he successfully applied for a Minority Travel Award from the Society of Toxicology (SOT) to attend the Annual Meeting in New Orleans. This experience provided Dr. Baines the opportunity to participate in two summer research internships in toxicology under SOT Past President, Dr. I. Glenn Sipes at the University of Arizona in Tucson. After graduating with a bachelor's degree in biology, he was admitted to the graduate program in pharmacology and toxicology at the University of Arizona. As a graduate student, he presented his research on colon cancer chemoprevention at various national scientific meetings including SOT and the American Association for Cancer Research. After receiving his PhD in Pharmacology and Toxicology in 2001, Tony accepted a postdoctoral fellowship at the University of North Carolina at Chapel Hill in pharmacology. His research focused on validating novel drug targets in pancreatic cancer for potential treatments. In August 2006, Dr. Baines accepted a faculty position in the Department of Biology and the Cancer Research Program at North Carolina Central University (one of 17 schools in the UNC system) in Durham, North Carolina where he currently teaches and conducts biomedical research on pancreatic cancer as an Associate Professor. In addition, he is an adjunct faculty member in the Department of Pharmacology and a member in the Curriculum in Toxicology at the University of Carolina at Chapel Hill. Last year in 2016, Dr. Baines was honored by receiving SOT's prestigious Undergraduate Educator Award. During his free time, Dr. Baines likes to jog, play basketball, practice martial arts, watch movies, read, travel, and most importantly, spend quality time with his family.

Yvonne Will

Pfizer Inc.
Drug Safety Research and Development
Eastern Point Road
Groton, CT 06340
860.686.2832
yvonne.will@pfizer.com

Dr. Yvonne Will was born and raised in Germany where she conducted her undergraduate studies in Human Nutrition at the University of Bonn, while working as a full time position in the Department of Equine Exercise Physiology. In 1992, Dr. Will conducted an internship at the College of Veterinary Medicine at Oregon State University, where she enrolled the same year to obtain her MS degree. Her work was focused on the bioremediation of explosives using ruminant bacteria and analytical chemistry approaches. In 2000, Dr. Will obtained her PhD in Biochemistry and Biophysics from Oregon State University, where her thesis focused on the relationships between glutathione deficiency, and cellular and mitochondrial function/dysfunction. During her years at the biotechnology company MitoKor, San Diego (2000-2003) she was involved in drug discovery aimed on improving mitochondrial function or preventing mitochondrial dysfunction in obesity, diabetes, and CNS related diseases. From 2003 until 2007, Dr. Will was a group leader in Drug Safety at Pfizer La Jolla, pioneering a screening paradigm for drug induced mitochondrial toxicity, supporting many therapeutic areas. This platform has been adapted throughout all major pharmaceutical companies. During that time she also held an adjunct faculty position at San Diego State University in the Toxicology program where she conducted lectures, taught laboratory courses and mentored MS students. In the fall of 2007, Dr. Will transferred to Pfizer Groton to lead a group of scientists in the Compound Safety Prediction Group within Medicinal Chemistry. This group was set out to conduct *in vitro* safety assessment as early as possible within the drug discovery process to reduce late stage attrition. Dr. Will's group has pioneered many new technologies throughout the years. Dr. Will has published a book on drug induced mitochondrial toxicity and is currently on a new book on drug discovery toxicology. Dr. Will has given many national and international lectures, conducted workshops and seminars and continues to publish numerous papers each year in peer reviewed journals, including a book on "Drug Induced Mitochondrial Toxicity" in 2008 and a book on "Drug Discovery Toxicology" in 2016. In 2012, Dr. Will was honored with the Connecticut Technology Council's Woman Research Innovation and Leadership Award. Dr. Will's passion is to develop young scientists through external influence such as publications and participations in national meetings. Dr. Will is the Head of Science and Technology for Drug Safety within Pfizer and lead of the Drug discovery Toxicology Efforts for Drug Safety-She works on strategy as well as innovation and developing the next generation of scientists through a postdoctoral program as well as mentoring efforts. Dr. Will is a Fellow of the Academy of Toxicological Sciences.

Patrick Allard

University of California Los Angeles
Environmental Health Science
650 Charles Young Drive S
CHS 56-070
Los Angeles, CA 90095
310.825.5257
pallard@ucla.edu

Patrick Allard received his BSc from University of Toulouse, France, and his MSc in Biology of Aging from University of Paris - Rene Descartes. He completed his PhD degree in Biology from the McGill University, Canada, in the laboratory of Dr. Hugh Clarke where he explored the genetic regulation of mammalian oogenesis. This work was followed by two concurrent postdoctoral fellowship positions in the laboratories of Dr. Clifford Tabin and Dr. Monica Colaiacovo in the Department of Genetics at Harvard Medical School. Dr. Allard's work resides at the intersection of genetics, epigenetics, developmental biology, and environmental health. His research on the effect of environmental exposures on reproduction has been published in several high profile journals including Proceedings of the National Academy of Sciences (PNAS), PLOS Genetics and Environmental Health Perspectives. Dr. Allard has received multiple awards and grants including the Colgate-Palmolive research grant, the Johns Hopkins Center for Alternatives to Animal Research grant, and most notably, a NIH K99/R00 Pathway to Independence Award as well as a Burroughs Wellcome Innovations in Regulatory Science Award. He was also received a Global ToxScholar Grant from the Society of Toxicology in 2011 and 2014.

Michael J. McCabe, Jr.

Robson Forensic Inc.
354 N Prince Street
Lancaster, PA 17603
717.286.9328
mmccabe@robsonforensic.com

Dr. McCabe is an internationally-trained and nationally recognized scientist with both research and teaching experience. He has a broad-based background in toxicology with specialized expertise in mechanistic immunotoxicology and human health assessment. Dr. McCabe earned his MS and PhD degrees in Microbiology and Immunology from Albany Medical College, NY, and completed post-doctorate training at the Karolinska Institute in Sweden. He is an active member in many professional associations including the Society of Toxicology and has served on numerous national and international advisory committees for the National Institutes of Health (NIH), the National Academy of Sciences, the US Environmental Protection Agency, and the World Health Organization. He sits on the editorial board of four toxicology journals, has been widely published, and has received numerous research grants from NIH. Dr. McCabe applies his expertise in toxicology to issues involving exposures to agents such as metals, solvents, PCBs/dioxins, and pesticides; blood alcohol, recreational drugs and substance abuse; food allergies; dermal reactions; and cosmetic product liability. He has spent more than 24 years working in the field of toxicology studying the adverse effects of chemical, physical, and biological agents on living organisms.

Marquea D. King



US Environmental Protection Agency
Office of Pesticide Programs
1200 Pennsylvania Ave NW
Washington, DC 20460
703.305.7432
king.marquea@epa.gov

Dr. King began her career with the US Environmental Protection Agency (US EPA) in Washington, DC, as a postdoctoral scholar in the area of inhalation toxicology. Beginning in the Office of Pesticide Programs (OPP) in 2007 in the Health Effects Division, she now works in the Pesticide Re-evaluation Division as a chemical review manager. She has been a member of the US EPA Pyrethroid Workgroup and the Atrazine Team; both committees were designated to tackle complex scientific issues for chemical registration. She has been the chair and a standing member on the Toxicology Scientific Advisory Committee, which provides support to chemical risk assessment teams. She has completed the Partnership for Public Service Excellence in Government Fellows Program and the Agency's Successful Leaders program. She has been Team Leader for the Special Emphasis Program Managers for OPP for five years, a group including seven different affinity groups; she has also chaired the National Black Employment Program Advisory Council, working with senior management in the Offices of Civil Rights, Diversity, Outreach, and Collaboration, and Human Resources, to integrate policies, programs, and serve as a resource for dissemination of information about underrepresented groups within the Agency. Dr. King completed her undergraduate degree in Chemistry from Delaware State University and her doctoral degree in Toxicology from Virginia Polytechnic Institute & State University in immunotoxicology and heavy metals. She is affiliated with the Southern Regional Education Board (SREB) and the Society of Toxicology where she is a member of the Committee for Diversity Initiatives. She is a board member at her local Boys & Girls Club and an active member of Delta Sigma Theta Sorority. She resides in Delaware rearing and raising her amazingly talented and very active sons.

Myrtle A. Davis

Toxicology and Pharmacology Branch
National Cancer Institute
9609 Medical Center Drive
MSC 9734
Bethesda, MD 20892
240 276-5915
myrtledavis@mail.nih.gov

Getting Started: Steps on the way to a Science Career in Academia, Industry or Government

During her interactive presentation, Dr. Davis will provide an overview of her career path and highlight the most important lessons learned.

The ultimate goal is to encourage participants to identify some of the major questions they should consider as they make decisions about graduate education and career choices.

Myrtle Davis, DVM, PhD, is the currently the Branch Chief for Toxicology and Pharmacology (DTP) in the Developmental Therapeutics Program of the Division of Cancer Diagnostics and Treatment of the National Cancer Institute (DCTD) and serves as Scientific Director of the Laboratory of Investigative Toxicology at the Frederick National Laboratory for Cancer Research (FNLCR). Dr. Davis contributes broadly to the DCTD by providing mechanistic toxicology expertise to drug discovery and development teams, creating and leading major research initiatives within DTP, and managing the daily operations of the Toxicology and Pharmacology Branch. The branch is responsible for developing safety evaluation strategies to establish toxicology profiles for investigational agents in the NCI's Experimental Therapeutics Program (NExT). The branch also provides expertise in discussions with the FDA about the design and adequacy of planned (or completed) nonclinical toxicology studies that are expected to support Investigational New Drug Applications. Prior to her appointment at NCI in 2008, Dr. Davis was a Research Advisor in the Investigative Toxicology Group at Lilly Research Labs, Eli Lilly and Company. Prior to taking the position at Eli Lilly in 2002, Dr. Davis was an Associate Professor in the Department of Pathology at the University of Maryland, School of Medicine, where she had an active grant-supported research program exploring mechanisms of toxicant-induced apoptosis and the role of protein phosphorylation. Dr. Davis is an active member of the Society of Toxicology and is a long-standing member of the Society of Toxicological Pathology. She has served on SOT Council and is on the Board of Trustees for the ILSI Health and Environmental Sciences Institute. She was a member of the Institute for Laboratory Animal Research (ILAR) Council, The National Academies of Sciences, for a six-year term ending in 2012. She served as Co-Editor in Chief for the ILAR Journal and has served and an Associate Editor for various toxicology journals including *Toxicological Sciences*. She also served as a member of the standing NIH Study Section ALTX1 for five years. She has authored several book chapters and co-authored peer-reviewed publications on a range of topics including apoptosis, toxicant-induced cell signaling, and biomarkers of tissue injury. She has also developed course content and lectures for medical and graduate student education. A native New Yorker, Dr. Davis completed a postdoctoral fellowship in Toxicologic Pathology at the University of Maryland. She earned a PhD in Toxicology from the University of Illinois Champaign-Urbana and obtained her Doctor of Veterinary Medicine degree from Tuskegee University School of Veterinary Medicine. She also completed undergraduate work in Chemistry and Math at Tuskegee University.